Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma

Authors
Publication date
1 January 2012
Publisher
'American Society of Clinical Oncology (ASCO)'
Doi

    Abstract

    Abstract is not available.

      Similar works

      Full text

      thumbnail-image

      Available Versions

      Archivio della Ricerca - Università degli Studi di Siena

      redirect
      oaioai:usiena-air.unisi.it:11365/...
      Last time updated on 17/10/2019